|
|
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-10-3078.
 Previous Article | Table of Contents | Next Article 
Blood, 1 May 2003, Vol. 101, No. 9, pp. 3708-3713
TRANSFUSION MEDICINE
Monoclonal IgG can ameliorate immune thrombocytopenia in a
murine model of ITP: an alternative to IVIG
Seng Song,
Andrew R. Crow,
John Freedman, and
Alan H. Lazarus
From Transfusion Medicine Research and the Department
of Laboratory Medicine and Pathobiology, St Michael's Hospital,
Toronto, ON; and the Canadian Blood Services and the Toronto Platelet
Immunobiology Group, ON, Canada.
Intravenous immunoglobulin (IVIG) is used to treat immune
thrombocytopenia resulting from a variety of autoimmune and
nonautoimmune diseases such as idiopathic thrombocytopenic purpura
(ITP), heparin-induced thrombocytopenia, and posttransfusion purpura.
IVIG is a limited resource and although considered safe, may
nevertheless carry some risk of transferring disease. Its high cost
makes monoclonal antibodies, capable of mimicking the clinical effects
of IVIG, highly desirable. We show here, using a murine model of ITP,
that selected monoclonal antibodies can protect against
thrombocytopenia. SCID mice were pretreated with 1 of 21 monoclonal antibodies before induction of thrombocytopenia by
antiplatelet antibody. Four antibodies reacted with the CD24
antigen on erythrocytes. Two antibodies were of the IgM
class, and although one IgM antibody caused a minimal degree of
anemia (P < .05), neither antibody ameliorated immune
thrombocytopenia. One of 2 anti-CD24 antibodies of the IgG class
ameliorated immune thrombocytopenia and blocked
reticuloendothelial system function at the same doses that protected
against thrombocytopenia. Some antibodies reactive with other
circulating cell types also protected against immune-mediated
thrombocytopenia while no antibody without a distinct target antigen in
the mice was protective. Protective monoclonal antibodies significantly
prevented thrombocytopenia at down to a 1000-fold lower dose (200 µg/kg) as compared with standard IVIG treatment (2 g/kg). It is
concluded that monoclonal IgG with specificity for a circulating
cellular target antigen may provide an alternative therapeutic approach
to treating immune thrombocytopenia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Speer, M. Schmugge, I. Azzouzi, M. L. Rand, and S. Kroiss
Apoptosis in Platelets from Pediatric Patients with Acute Immune Thrombocytopenic Purpura (ITP) Is Ameliorated by IV Ig.
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
3417 - 3417.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor
Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models
J. Immunol.,
September 15, 2007;
179(6):
4263 - 4271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Deng and J. P. Balthasar
Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia
Blood,
March 15, 2007;
109(6):
2470 - 2476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Crow, S. Song, J. W. Semple, J. Freedman, and A. H. Lazarus
A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?
Blood,
January 1, 2007;
109(1):
155 - 158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Olsson, P. Bruhns, W. A. Frazier, J. V. Ravetch, and P.-A. Oldenborg
Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia
Blood,
May 1, 2005;
105(9):
3577 - 3582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Song, A. R. Crow, V. Siragam, J. Freedman, and A. H. Lazarus
Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg
Blood,
February 15, 2005;
105(4):
1546 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lamoureux, E. Aubin, and R. Lemieux
Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg?
Int. Immunol.,
July 1, 2004;
16(7):
929 - 936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
